(IN BRIEF) The Institute of Cancer Research, London, has led the development of OPTIMISE-ROR, the first structured guidance outlining how patient-reported outcomes should be used in early-stage cancer dose-finding trials. Published in the Journal of Clinical Oncology, the recommendations provide … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Cancer Research UK, Christina Yap, clinical trials methodology, dose-finding studies, early-stage cancer trials, Emily Alger, Experimental Cancer Medicine Centre, ICR, Institute of Cancer Research Develops First Foundational Framework for Patient-Reported Outcomes in Early Oncology Trials, Institute of Cancer Research London, International Study Led by ICR Strengthens Role of Patient Experience in Early-Phase Cancer Drug Development, Journal of Clinical Oncology, oncology research, OPTIMISE-ROR, patient-reported outcomes, PROs
(IN BRIEF) In recognition of World Statistics Day 2025, The Institute of Cancer Research (ICR), London, is spotlighting the essential role of statisticians in advancing cancer research through reliable, transparent, and responsible data analysis. The event, themed “Quality statistics and … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adaptive trial designs, artificial intelligence, biostatistics, cancer trials, clinical research, Clinical Trials and Statistics Unit, Covid-19 pandemic, CTSU, data transparency, Emily Alger, evidence-based decision making, ICR, ICR showcases how statistical science powers cancer research and clinical progress for World Statistics Day 2025, Machine Learning, oncology research, patient-reported outcomes, Professor Christina Yap, quality statistics, responsible research, statistical science, The Institute of Cancer Research celebrates the power of statistics in advancing cancer research ahead of World Statistics Day 2025, The Institute of Cancer Research London, University of Oxford, University of Warwick, World Statistics Day 2025
(IN BRIEF) Novo Nordisk has received a positive opinion from the European Medicines Agency’s CHMP recommending label expansion for Alhemo® (concizumab) to include adolescents and adults with haemophilia A and B without inhibitors. Backed by robust data from the explorer8 … Read the full press release
Posted in Business, Denmark, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Alhemo®, bleeding disorder, CHMP, concizumab, EMA, European Commission, explorer8 trial, Haem-A-QoL, Haemophilia A, haemophilia B, haemophilia treatment, Martin Holst Lange, monoclonal antibody, Novo Nordisk, patient-reported outcomes, pen-injector, SF-36v2, subcutaneous prophylaxis, thrombin production, tissue factor pathway inhibitor
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?